Related Experiment Video
Updated: Apr 8, 2026

Isolation, Transfection, and Culture of Primary Human Monocytes
Published on: December 16, 2019
The role of statins in the setting of HIV infection
Allison Ross Eckard1, Grace A McComsey
1Departments of Pediatrics and Medicine, Divisions of Infectious Diseases, Medical University of South Carolina, 135 Rutledge Ave, MSC 752, Charleston, SC, 29425, USA, eckarda@musc.edu.
Insights
Statins may reduce cardiovascular disease (CVD) risk in people with HIV. These drugs lower lipids and inflammation, potentially mitigating HIV-related complications.
Area of Science:
- Cardiology
- Infectious Diseases
- Pharmacology
Background:
- Individuals with HIV face higher risks of cardiovascular disease (CVD) and other comorbidities.
- Antiretroviral therapy (ART) can cause dyslipidemia, while chronic HIV infection increases inflammation and immune activation, contributing to CVD risk.
Purpose of the Study:
- To review current literature on the use of statins in HIV-infected individuals.
- To evaluate the potential benefits of statins in reducing CVD and non-AIDS-defining comorbidities in this population.
Main Methods:
- Literature review of recent studies on statin use in HIV patients.
- Analysis of statin's lipid-lowering, anti-inflammatory, and immunomodulatory effects.
Main Results:
- Statins possess significant lipid-lowering capabilities.
- Statins demonstrate anti-inflammatory and immunomodulatory properties.
- Emerging evidence suggests statins may decrease CVD risk in HIV-infected individuals.
Conclusions:
- Statins are a promising therapeutic option for managing CVD risk in HIV patients.
- The anti-inflammatory and immunomodulatory effects of statins may offer additional benefits beyond lipid reduction.
- Further research is warranted to confirm the long-term efficacy and safety of statins in the HIV population.
Abstract:
HIV-infected individuals are at an increased risk of cardiovascular disease (CVD) and other HIV-related co-morbidities. This is due in part to dyslipidemia associated with antiretroviral therapy and increased inflammation and immune activation from chronic HIV infection. Statins not only have potent lipid-lowering properties but are also anti-inflammatory and immunomodulators. Studies suggest that statin therapy in the HIV-infected population may decrease the risk of CVD and other non-AIDS-defining co-morbidities. This review summarizes the recent literature on statin use in the HIV setting.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Sexually Transmitted Infections
Retrovirus Life Cycles
Inhibitors of Viral Protein Synthesis
Cholesterol: Significance and Regulation
Considering cholesterol and...
Size and Structure of Viral Genomes

